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(H. Peng).Diabetic nephropathy (DN) is a major diabetic complication. But the initiating molecular events trig-
gering DN are unknown. Recent researches have addressed the role of microRNAs in diabetes and its
complications. In this study, we looked for microRNAs expression during early DN, and showed
microRNA-21 (miR-21) expression was downregulated in response to early DN in vitro and
in vivo. Over-expression of miR-21 inhibited proliferation of mesangial cells and decreased the
24-h urine albumin excretion rate in diabetic db/db mice. Moreover, we identiﬁed PTEN as a target
of miR-21. We also found PI3 K and p-Akt increased in miR-21 treated mesangial cells and db/db
mice. Overall, these studies for the ﬁrst time provide evidence for the potential role of miR-21 in
early DN.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Diabetes is the leading cause of end-stage renal failure, and
much of the morbidity and mortality of diabetes can be attributed
to nephropathy. Diabetic nephropathy (DN) is characterized early
in its course by glomerular hypertrophy and, importantly, mesan-
gial hypertrophy, which is associated with the eventual glomerulo-
sclerosis [1]. Despite the great progresses that have been made in
recent decades, the mechanism involved in mesangial hypertrophy
is not fully understood.
MicroRNAs (miRNAs) are a group of endogenous, small non-
coding RNAs that can modulate protein expression [2]. Recently,
it has been reported that miRNAs play a role in diabetes mellitus
and its complications [3]. The pancreatic islet-speciﬁc miRNA,
miR-375, plays a negative role in insulin secretion, and it is also
a key determinant of blood homeostasis [4]. The over-expression
of miR-29 aggravates insulin resistance [5]. MiR-133 promotes dia-
betic cardiopathy by inhibiting kalium ion channel of ERG gene,
indicating the participation of miRNAs in diabetes mellitus andchemical Societies. Published by E
f Cell Biology and Medical
cal College Road, Chongqing,
ng), penghuimin6@sohu.comits complications [6]. However, the role of miRNAs in mediating
mesangial hypertrophy of DN has never been studied.
In this study, we investigated the potential role of miRNA in
mesangial hypertrophy during early DN in vitro and in vivo.
Through a screen with miRNA array, we identiﬁed miR-21 as a reg-
ulator of early DN. First, over-expression of miR-21 inhibited pro-
liferation of mesangial cells in high glucose condition. In
addition, the 24-h urine albumin excretion rate (UAE) of diabetic
db/db mice was decreased after being treated with plasmids con-
taining miR-21 (30 mg/kg/d) for 4 weeks. Consistent with its func-
tion in vitro and in vivo, miR-21 regulates the expression of the
DN-related genes, including PTEN [7], which has a role in organ
size [8,9]. This has been well established. Taken together, our re-
sults strongly suggest that there is an important regulatory role
of miR-21 in DNmesangial cell proliferation, implying that it might
be a novel potential target for intervention and prevention of DN.
2. Materials and methods
2.1. Animals
C57BL/6JLepr background db/db, db/m mice from SLACCAS
(Shanghai, China) were used and the guidelines on humane use
and care of laboratory animals for biomedical research published
by NIH (No. 85-23, revised 1996) were strictly complied for alllsevier B.V. All rights reserved.
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db/m controls were killed for microarray and cell culture studies
when signiﬁcant elevation of UAE was detected in db/db mice.
Glomeruli were taken from mice in both groups and were sieved
from renal cortical tissue, as described previously [10]. A further
48 male mice at 4 weeks of age were randomized into 4 groups:
control group (12 normal untreated db/m mice), miR-21-treated
db/db group (12 mice), empty plasmid pGenesil-1-treated db/db
group (12 mice), or untreated db/db group (12 mice). Mice were in-
jected intraperitoneally with plasmids (30 mg/kg/d of miR-21 or
30 mg/kg/d of pGenesil-1) until UAE was signiﬁcantly higher in
the untreated db/db mice than the db/m normal control mice.
Whole blood was obtained from the retro-orbital sinus of fed mice,
and glucose and UAE were measured using an automatic biochem-
istry analyzer (Hitachi Ltd., Tokyo, Japan). After mice were killed,
cortical sections of both kidneys from each mouse were pooled.
A slice of renal cortical tissue from each mouse was also immedi-
ately frozen in liquid nitrogen for later use.
2.2. Cell culture, cloning and expression of miR-21
Primarymousemesangial cells isolatedandculturedasdescribed
previously [7,10], cultured inRPMI1640mediumwith5 mmol/l glu-
coseand10% fetalbovineserum(FBS).Mmu-miR-21genesequences
were selected from themiRBase at http://microrna.sanger.ac.uk/se-
quences/. Mir-21 (mmu-miR-21, MIMAT0000530) was chemically
synthesized (Takara Shuzo, Shiga, Japan), and contained a SacI
restriction enzyme cut site: mmu-miR-21-A 50-CACCTAGCTTATCA
GACTGATGTTGATTTTTTG-30; mmu-miR-21-B 50-AGCTCAAAAAAT
CAACATCAGTCTGATAAGCTA-30. The DNA segments were cloned
into pGenesil-1 expression vectors (Wuhan Genesil Biotechnology
Co. Ltd., Wuhan, China) and conﬁrmed by DNA sequencing. The
expression of miR-21 was induced by transfection of the plasmid
into the cells using Lipofectamine2000 (Invitrogen, CA,USA) accord-
ing to themanufacturer’s instructions. Cellsweremaintained in ser-
um-free medium with 5 mmol/l glucose for 24 h, which was
followed by incubation with fresh serum-free medium with 25
mmol/l glucose (high glucose) for 48 h. Control cellswere incubated
with 5 mmol/l glucose plus 20 mmol/l mannitol (low glucose) for
48 h. Mesangial cells in this study were divided into four groups:
cells in low glucose as the normal control group, a miR-21-transfec-
ted high glucose group, empty plasmid pGenesil-1-transfected high
glucose group, and untransfected high glucose group.
2.3. Isolation of total RNA
RNA was extracted by Trizol reagent (Invitrogen) as standard
method.
2.4. MiRNA microarray
Small RNA separating, quality control, labeling, hybridization
and scanning were performed by LC Sciences (Houston, TX, USA)
using miRMouse_10.0_071620 miRNA array chip, based on Sanger
miRBase Release 10.0. The array was repeated twice. Preliminary
statistical analysis was performed by LC sciences on mean value
normalized by Locally-weighted Regression (LOWESS) method on
the background-subtracted data. Then, Student’s test was per-
formed to identify the different miRNA expression. MiRNAs with
P < 0.01 was considered as having signiﬁcant difference between
DN and control.
2.5. Real time reverse transcription (RT)-PCR
MiR-21 expression was measured by real time RT-PCR (details
shown in Supplementary data).2.6. Growth inhibition test
MTT Cell Proliferation Assay Kit (Invitrogen) was employed to
analyze cell proliferation (details shown in Supplementary data).
2.7. Glomerular morphological observation
Sieved renal glomeruli taken from mice were observed and
measured under the microscope with a micrometer. The average
diameter of 100 glomeruli in a group was counted in three differ-
ent visual ﬁelds.
2.8. Bioinformatics analysis
Three programs, PicTar, miRanda, and TargetScan [11–13], were
used to predict the targets of miR-21.
2.9. Western blot analysis
PTEN, PI3K p85a and phospho-Akt (Ser473) proteins were mea-
sured by Western blot using mouse anti-PTEN (Santa Cruz, CA),
mouse anti-PI3K (Santa Cruz, CA) and rabbit anti- phospho-Akt
(Cell Signaling Technology, Beverly, MA), respectively (details
shown in Supplementary data).
2.10. Immunocytochemistry and immunohistochemistry
PTEN protein of mesangial cells was analyzed by immunocyto-
chemistry, and PTEN protein of renal tissues was tested by immu-
nohistochemistry using mouse anti-PTEN (Santa Cruz, CA) (details
shown in Supplementary data). The average gray value of 50 sec-
tions in each group was measured by Beihang CM-2000 Biomedical
Image Analysis System software (Beihang, Beijing, China).
2.11. Immunoﬂuorescence staining
PI3K p85a and phospho-Akt (Ser473) proteins were detected by
immunoﬂuorescence using mouse anti-PI3K (Santa Cruz, CA) and
rabbit anti-phospho-Akt antibody (Cell Signaling Technology),
respectively (details shown in Supplementary data).
2.12. Statistical analysis
All statistical tests were performed using SPSS software (SPSS,
Chicago, IL). Comparisons between groups were carried out by AN-
OVA or Kruskal–Wallis tests, as appropriate, according to the
Gaussian or non-Gaussian distribution of the data. Changes in each
group were analyzed using one-way ANOVA or non-parametric
tests. P-values < 0.05 were considered statistically signiﬁcant. All
data are presented as means ± standard deviation (S.D.).
3. Results and discussion
3.1. Reduced expression of miR-21 in db/db DN mice
To study the potential role of miRNA in DN, we used the miR-
Mouse_10.0_071620 miRNA array, which contained 568 probes,
to scan miRNAs that were differentially expressed between db/db
DN mice and controls. We used db/db mice with hyperglycemia
and signiﬁcant elevation of urinary albumin excretion were used
as animal model of the early stage of DN because db/db mice de-
velop kidney disease with similarities to human diabetic nephrop-
athy [14]. Among 568 miRNAs screened, 66 miRNAs exhibited
signiﬁcantly different expression level between glomerular tissues
of db/db DN mice and db/m controls (Supplementary Table 1). Of
Table 1
Body weight, blood glucose and UAE of mice.
Groups Body weight (g) Blood glucose (mmol/l) 24-h urine albumin excretion (UAE; lg/24 h)
4 weeks
The miR-21-treated db/db group 18.5 ± 0.3** 10.1 ± 1.2* 11.7 ± 1.1
The pGenesil-1-treated db/db group 18.9 ± 0.6** 10.1 ± 1.0* 11.5 ± 0.7
The untreated db/db group 19.5 ± 0.2** 10.2 ± 0.5* 11.0 ± 1.2
The control db/m group 13.6 ± 0.1 8.8 ± 0.6 10.4 ± 0.7
8 weeks
The miR-21-treated db/db group 29.0 ± 1.4** 20.1 ± 3.7** 22.5 ± 7.1
The pGenesil-1-treated db/db group 29.9 ± 1.5** 27.6 ± 4.7** 88.0 ± 13.8**,***
The untreated db/db group 31.2 ± 1.5** 24.4 ± 3.8** 91.8 ± 9.9**,***
The control db/m group 18.6 ± 1.2 9.9 ± 0.5 11.5 ± 0.9
* P < 0.05 vs. controls.
** P < 0.01 vs. controls.
*** P < 0.01 vs. the miR-21-treated group.
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of the most obviously altered miRNAs and inhibited cell growth
in many pathological changes [15–17]. Consistent with the array
results, real-time RT-PCR further validated that down-regulation
of miR-21 in DN was a recurrent event (Supplementary Fig. 1A).
Together, it suggested that expression level of miR-21 was inver-
sely related to DN.
3.2. Over-expression of miR-21 in miR-21-transfected cells and miR-
21-treated mice kidneys
Results of real-time RT-PCR showed that miR-21 was signiﬁ-
cantly increased in the miR-21-transfected cells compared with
the empty plasmid pGenesil-1-transfected cells (P < 0.01), suggest-
ing miR-21 can be over-expressed by Lipofectamine 2000 transfec-
tion in the cells (Supplementary Fig. 1B). Also, the expression of
miR-21 was signiﬁcantly enhanced in the kidneys of miR-21-trea-
ted db/db mice compared with the pGenesil-1-treated mice
(P < 0.01). It suggested that miR-21 was over-expressed in the kid-
neys of miR-21-treated db/db mice by injection plasmids contain-
ing miR-21 (30 mg/kg/d) for 4 weeks (Supplementary Fig. 1C).
3.3. MiR-21 prevents mesangial cells proliferation in vitro
We cultured mesangial cells under high glucose conditions to
mimics diabetic pathology [7]. The cloning of miR-21 is shown in
Supplementary Fig. 2. The cells proliferation of cells in the miR-
21-transfected group was signiﬁcantly inhibited compared with
the empty plasmid pGenesil-1-transfected and untransfected
groups (all: P < 0.01). Thus, our results showed that miR-21 inhib-
ited mesangial cells proliferation in high glucose conditions (Sup-
plementary Fig. 3).
3.4. Effects of miR-21 on biochemical parameters and glomerular
morphology in vivo
At 4 weeks of age, db/db mice already showed signiﬁcant
hyperglycemia, whereas UAE did not increase compared with db/
m mice (Table 1). At 8 weeks of age, db/db mice showed signiﬁcant
elevation of UAE (Table 1). Thus, 4-week-old db/db mice exhibited
features similar to the human normoalbuminuric stage, and 8-
week-old mice showed features similar to the human early stage
of diabetic nephropathy.
Plasmids containing miR-21 (30 mg/kg/d) were injected into 4-
week-old db/db mice for 4 weeks. Body weight and blood glucose
were signiﬁcantly higher in the three diabetic groups compared
with the normal control group between 4 and 8 weeks of age,
but there were no signiﬁcant differences between the three dia-
betic groups. Additionally, UAE did not differ signiﬁcantly betweenthe four groups of mice at 4 weeks of age. However, in the 8-week-
old mice (i.e., 4 weeks after starting injection of plasmids), UAE
was signiﬁcantly decreased in miR-21 treated group among the
three diabetic groups (Table 1).
The diameter of glomeruli of 8-week-old mice was signiﬁcantly
greater in the pGenesil-1-treated and untreated db/db groups than
that in the control group. Interestingly, it was smaller in miR-21-
treated group than in the pGenesil-1-treated and untreated groups
(Supplementary Fig. 4). Together, our results demonstrated that
miR-21 played a protective role in glomerular hypertrophy and
the onset of early DN.
3.5. PTEN was a target of miR-21 in DN
All known mRNA 30-UTRs were scanned as potential targets
for miR-21 by in silico analysis. Of all the miR-21 targets pre-
dicted, PTEN was found to be most appropriate. It was predicted
PTEN, which contained the binding site of miR-21 in its 30 UTR,
could be regulated by miR-21 (Supplementary Fig. 5). And it was
reported PTEN gene was a direct target of miR-21 by cloning a
fragment of the 30-UTR of PTEN mRNA containing the putative
miR-21-binding sequence into a ﬁreﬂy luciferase reporter con-
struct using the dual-luciferase reporter assay system (Promega)
in other diseases [18,19]. Interestingly, previous works have
demonstrated that PTEN expression was associated with DN
[7]. Therefore, it is tempting to speculate that over-expression
of miR-21 might prevent mesangial hypertrophy via down-regu-
lation of PTEN in DN.
To test this hypothesis, we examined PTEN protein expression
byWestern blot in vitro and in vivo. Our data showed PTEN protein
expression was reduced in the cells in the miR-21-transfected
group compared with the cells in the pGenesil-1-transfected and
the untransfected groups (Fig. 1A). Similarly, in the renal tissues
of 8-week-old db/db mice, PTEN protein levels were signiﬁcantly
decreased in the miR-21-treated group compared with the pGene-
sil-1-treated group and the untreated group (Fig. 1B).
Furthermore, the expression proﬁle of PTEN protein was re-
duced in cells (Fig. 1C and E) or animals (Fig. 1D and F) treated with
plasmid miR-21, as tested by immunohistochemistry. Our results
suggested that over-expression of PTEN may act as an originator
or promoter of DN, which is consistent with the report of Mahimai-
nathan [7]. Moreover, the proliferation of mesangial cells may be
delayed when PTEN was speciﬁcally inhibited by miR-21 in early
DN.
3.6. MiR-21 regulates the PI3K/Akt signal pathway
Western blotting revealed that PI3K p85a and phospho-Akt (Ser
473) were increased in the cells in miR-21-transfected group than
Fig. 1. MiR-21 can reduce PTEN protein expression in mesangial cells incubated in high glucose conditions and in db/db mice. (A) The protein expression of PTEN was
decreased in the miR-21-transfected cells compared with that in the pGenesil-1-transfected and untransfected cells. (B) Protein expression of PTEN was signiﬁcantly lower in
the kidneys of the miR-21-treated db/db mice group than that in the pGenesil-1-treated and untreated db/db mice groups. (C) Immunohistochemical analysis of PTEN protein
expression in mesangial cells showed PTEN was decreased in the miR-21-transfected cells compared with that in the pGenesil-1-transfected and untransfected cells. Arrows
indicate mesangial cells. Figures are shown at 200 magniﬁcation. (D) Immunohistochemical analysis of PTEN protein expression in the glomeruli of mice showed PTEN was
decreased in the miR-21-treated group compared with that in the pGenesil-1-treated and untreated groups. Arrows indicate renal glomerular tissue. Figures are shown at
400 magniﬁcation. (E) Bar graphs show the average gray value of PTEN protein level in cells of each group. Results are showed as means ± S.D. **P < 0.01 vs. controls,
NNP < 0.01 vs. the miR-21-transfected group. (F) Bar graphs show the average gray value of PTEN protein level in glomeruli of each group. Results are showed as means ± S.D.
**P < 0.01 vs. controls, NNP < 0.01 vs. the miR-21-treated group.
Fig. 2. Effect of miR-21 on protein levels of p-Akt (Ser 473) and PI3K p85a in DN. (A) In mesangial cells, p-Akt (Ser 473) and PI3K protein levels were signiﬁcantly higher in the
miR-21-transfected and control groups than that in the pGenesil-1-transfected and untransfected groups. (B) In db/db DN mice, p-Akt (Ser 473) and PI3K protein levels were
signiﬁcantly higher in the miR-21-treated and control groups than that in the pGenesil-1-treated and untreated groups.
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Moreover, in the renal tissues of 8-week-old db/db mice, PI3K
p85a and phospho-Akt (Ser 473) were increased in the miR-21-
treated group than those in the pGenesil-1-treated and the un-
treated groups (Fig. 2)
Dual-ﬂuorescence staining was used to assess the localiza-
tions of PI3K p85a and phospho-Akt (Ser 473) in renal tissues
of 8-week-old mice. PI3K protein was ﬂuorescently labeled with
FITC green and p-Akt (Ser 473) with labeled with TRITC red,
which were visualized with confocal laser scanning ﬂuorescence
microscopy. Merging both images (yellow-color) for the co-
expression of PI3K p85a and p-Akt (Ser 473) demonstrated thatthey were co-increased in the renal tissues in the miR-21-treated
group compared with those in the pGenesil-1-treated and the
untreated groups (Fig. 3). Interestingly, previous works have sug-
gested that the PI3K pathway is a crucial pathway involved in
the metabolic responses to insulin. Binding of insulin to the
insulin receptor activates the PI3K pathway. Defects in PI3K sig-
naling have been demonstrated in type 2 diabetes mellitus
[20,21]. Additionally, the PI3K pathway is altered in renal mes-
angial cells by advanced glycation end products (AGEs), which
contribute to diabetic complications, including DN [22]. The
main biological function of PTEN is to block PI3K signaling
[23]. These results link mesangial hypertrophy to miR-21 in
Fig. 3. Immunoﬂuorescence staining of PI3K (green) and p-Akt (red) by dual-ﬂuorescence staining. Merging of both images (yellow) showed co-localization of PI3K and p-Akt
(Ser473) in renal tissues of 8-week-old mice. Representative photographs were taken from renal tissues of the normal control (A), miR-21-treated (B), pGenesil-1-treated (C)
and untreated (D) groups. PI3K and p-Akt were increased in the renal tissues in the miR-21-treated group compared with those in the pGenesil-1-treated and untreated
groups. Arrows indicate renal glomerular tissue. Figures are shown at 400 magniﬁcation.
Z. Zhang et al. / FEBS Letters 583 (2009) 2009–2014 2013response to PTEN/Akt signaling, miR-21 could be a causal factor
of the down-regulation of PTEN and activation of PI3K/Akt
pathway in renal mesangial cell hypertrophy in early period of
DN.
In summary, miR-21 prevented mesangial hypertrophy by tar-
geting the PTEN/PI3K/Akt pathway in vivo and in vitro. Therefore,
miR-21 might play an important role in the pathogenesis of DN
and offers a potential target for intervention and prevention of
DN. Further investigations are required, including a larger number
of specimens, and more studies on the ‘‘crosstalk” of the network
over the deregulated miRNAs in DN are also needed.Acknowledgments
This work was supported by grants from the National Natural
Science Foundation of China (No. 30800534) and Scientiﬁc Re-
search Foundation of Chongqing Medical University of China (No.
NSFYY200719).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2009.05.021.
2014 Z. Zhang et al. / FEBS Letters 583 (2009) 2009–2014References
[1] Mason, R.M. and Wahab, N.A. (2003) Extracellular matrix metabolism in
diabetic nephropathy. J. Am. Soc. Nephrol. 14, 1358–1373.
[2] Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and
function. Cell 116, 281–297.
[3] Lagos-Quintana, M., Rauhut, R., Lendeckel, W. and Tuschl, T. (2001)
Identiﬁcation of novel genes coding for small expressed RNAs. Science 294,
853–858.
[4] Poy, M.N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., Macdonald, P.E.,
Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P. and Stoffel, M. (2004) A
pancreatic islet-speciﬁc microRNA regulates insulin secretion. Nature 432,
226–230.
[5] He, A., Zhu, L., Gupta, N., Chang, Y. and Fang, F. (2007) Overexpression of micro
ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin
resistance in 3T3-L1 adipocytes. Mol. Endocrinol. 21, 2785–2794.
[6] Xiao, J., Luo, X., Lin, H., Zhang, Y., Lu, Y., Wang, N., Zhang, Y., Yang, B. and Wang,
Z. (2007) MicroRNA miR-133 represses HERG K+ channel expression
contributing to QT prolongation in diabetic hearts. J. Biol. Chem. 282,
12363–12367.
[7] Mahimainathan, L., Das, F., Venkatesan, B. and Choudhury, G.G. (2006)
Mesangial cell hypertrophy by high glucose is mediated by downregulation
of the tumor suppressor PTEN. Diabetes 55, 2115–2125.
[8] Crackower, M.A., Oudit, G.Y., Kozieradzki, I., Sarao, R., Sun, H., Sasaki, T., Hirsch,
E., Suzuki, A., Shioi, T., Irie-Sasaki, J., Sah, R., Cheng, H.Y., Rybin, V.O., Lembo, G.,
Fratta, L., Oliveira-dos-Santos, A.J., Benovic, J.L., Kahn, C.R., Izumo, S., Steinberg,
S.F., Wymann, M.P., Backx, P.H. and Penninger, J.M. (2002) Regulation of
myocardial contractility and cell size by distinct PI3K-PTEN signaling
pathways. Cell 110, 737–749.
[9] Backman, S.A., Stambolic, V., Suzuki, A., Haight, J., Elia, A., Pretorius, J., Tsao,
M.S., Shannon, P., Bolon, B., Ivy, G.O. and Mak, T.W. (2001) Deletion of Pten in
mouse brain causes seizures, ataxia and defects in soma size resembling
Lhermitte–Duclos disease. Nat. Genet. 29, 396–403.
[10] Shultz, P.J., DiCorleto, P.E., Silver, B.J. and Abboud, H.E. (1988) Mesangial cells
express PDGF mRNAs and proliferate in response to PDGF. Am. J. Physiol. 255,
F674–684.[11] Krek, A., Grun, D., Poy, M.N., Wolf, R., Rosenberg, L., Epstein, E.J., Macmenamin,
P., da Piedade, I., Gunsalus, K.C., Stoffel, M. and Rajewsky, N. (2005)
Combinatorial microRNA target predictions. Nat. Genet. 37, 495–500.
[12] John, B., Enright, A.J., Aravin, A., Tuschl, T., Sander, C. and Marks, D.S. (2004)
Human MicroRNA targets. PLoS Biol. 2, e363.
[13] Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P. and Burge, C.B. (2003)
Prediction of mammalian microRNA targets. Cell 115, 787–798.
[14] Sharma, K., McCue, P. and Dunn, S.R. (2003) Diabetic kidney disease in the db/
db mouse. Am. J. Physiol. 284, F1138–F1144.
[15] Dahiya, N., Sherman-Baust, C.A., Wang, T.L., Davidson, B., Shih, I.M., Zhang, Y.,
Wood III, W., Becker, K.G. and Morin, P.J. (2008) MicroRNA expression and
identiﬁcation of putative miRNA targets in ovarian cancer. PLoS ONE 3, e2436.
[16] Ladeiro, Y., Couchy, G., Balabaud, C., Sage, P.B., Pelletier, L., Rebouissou, S. and
Zucman-Rossi, J. (2008) MicroRNA proﬁling in hepatocellular tumors is
associated with clinical features and oncogene/tumor suppressor gene
mutations. Hepatology 47, 1955–1963.
[17] Tatsuguchi, M., Seok, H.Y., Callis, T.E., Thomson, J.M., Chen, J.F., Newman, M.,
Rojas, M., Hammond, S.M. and Wang, D.Z. (2007) Expression of microRNAs is
dynamically regulated during cardiomyocyte hypertrophy. J. Mol. Cell Cardiol.
42, 1137–1141.
[18] Meng, F., Henson, R., Wehbe-Janek, H., Ghoshal, K., Jacob, S.T. and Patel, T.
(2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene
in human hepatocellular cancer. Gastroenterology 133, 647–658.
[19] Roy, S., Khanna, S., Hussain, S.R., Biswas, S., Azad, A., Rink, C., Gnyawali, S.,
Shilo, S., Nuovo, G.J. and Sen, C.K. (2009) MicroRNA expression in response to
murine myocardial infarction: miR-21 regulates ﬁbroblast metalloprotease-2
via phosphatase, tensin homologue. Cardiovasc. Res. 82, 21–29.
[20] Cantley, L.C. (2002) The phosphoinositide 3-kinase pathway. Science 296,
1655–1657.
[21] Jiang, G. and Zhang, B.B. (2002) Pi 3-kinase and its up- and down-stream
modulators as potential targets for the treatment of type II diabetes. Front.
Biosci. 7, 903–907.
[22] Xu, D. and Kyriakis, J.M. (2003) Phosphatidylinositol 30-kinase-dependent
activation of renal mesangial cell Ki-Ras and ERK by advanced glycation end
products. J. Biol. Chem. 278, 39349–39355.
[23] Sulis, M.L. and Parsons, R. (2003) PTEN: from pathology to biology. Trends Cell
Biol. 13, 478–483.
